Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
04:01pm, Monday, 11'th May 2020
The pharma giant and the smaller biotech will keep working together on a couple of promising CAR-T cancer therapies.
Bristol Myers to pay bluebird $200 million for future royalties on cancer therapies
03:22pm, Monday, 11'th May 2020
The treatments, ide-cel and bb21217, are part of a class of drugs called CAR-T therapies that involve drawing white blood cells from a patient, processing them to target cancer cells, and infusing the
Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates
12:25pm, Monday, 11'th May 2020
Bluebird (BLUE) delivered earnings and revenue surprises of 7.61% and 147.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement
11:35am, Monday, 11'th May 2020
bluebird bio, Inc. (NASDAQ: BLUE) today announced that it has amended its existing co-promotion/co-development agreement with Bristol Myers Squibb (BMS) to enable the companies to focus their efforts
bluebird bio Provides Operational and Business Update and Reports First Quarter 2020 Financial Results
11:00am, Monday, 11'th May 2020
bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2020 and provided an operational update.
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
Is a Surprise Coming for bluebird bio (BLUE) This Earnings Season?
01:55pm, Friday, 08'th May 2020
bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
bluebird bio, Inc. (Nasdaq: BLUE) announced today that updated results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of idecabtagene vicleucel (ide-cel; bb2121), an investig
bluebird bio Reports Updated Results From Pivotal Phase 2 KarMMa Study At ASCO 2020 Virtual Program
12:00am, Friday, 08'th May 2020Errant Gene Therapeutics (EGT) Wins Major Victory in New York Appeals Court
12:00am, Thursday, 07'th May 2020
Errant Gene Therapeutics (EGT) Wins Major Victory in New York Appeals Court
Better Buy: Crispr Therapeutics vs. bluebird bio
10:27am, Thursday, 30'th Apr 2020
Who wins in a matchup between these two gene-editing leaders?
